(Source = KB Securities)
Next week, the JPMorgan Healthcare Conference, one of the biggest events in the pharmaceutical and bio industry, will be held. A number of promising pharmaceutical and bio companies at home and abroad will participate to discuss technology contracts and mergers and acquisitions (M&A). Several companies, including Hanmi Pharm and Yuhan Corporation, have announced the news of large-scale technology transfer at this conference. Accordingly, investors are also keen to find K-Bio who will launch the next’jackpot’.
According to the related industry on the 8th, the 39th JPMorgan Healthcare Conference will be held online on the 11th to 14th (local time). More than 10,000 people from 500 companies around the world are expected to participate in this event. Among the domestic pharmaceutical and bio companies, six companies including Samsung Biologics, Hanmi Pharm, LG Chem, Huzel, HK Innoen, and Genexin were scheduled to be announced. In addition, many companies hold 1:1 partnership meetings on the spot.
First of all, the market is interested in Samsung Biologics, the only company in charge of the main track announcement. As it is the first official stage after the transition to the new CEO of John Lim, it is expected that the mid- to long-term vision and management strategy changes will be mentioned. Representative John Lim will announce on the morning of the 13th.
The companies announced on the Emerging Market are Hanmi Pharmaceutical, LG Chem, Huzel, HK Innoen, and Genexine in that order.
Huzel plans to announce its strategy to advance into China for its botulinum toxin drug’Retivo’ and a three-year growth strategy. This year, Huzel is aiming to apply for Letivo’s European license and US product license.
LG Chem is focusing on the status of its new drug pipeline and its mid- to long-term business strategy. LG Chem is conducting phase 2 clinical trials for gout treatment, phase 2 treatment for autoimmune diseases, phase 1 treatment for rare obesity, and phase 1 treatment for non-alcoholic steatohepatitis.
Genexine will be introduced mainly with’persistent interleukin-7 (GX-I7)’. GX-I7 is a new drug substance being developed as an anticancer drug and corona treatment. Genexine recently acquired a stake in Toolgen, which owns CRISPR genetic shear technology.
HK Innoen, ahead of IPO, is also raising expectations. Along with the company introduction, the company plans to introduce the achievements of the new gastroesophageal reflux disease drug’Kcap’ and its strategy to advance globally. Major new drug candidates such as a new drug for autoimmune diseases (IN-A002), a new drug for non-alcoholic steatohepatitis (IN-A010), and a hand, foot and mouth vaccine (IN-B001) will also be announced.
Hanmi Pharm is also unveiling its major business plans and R&D vision this year. Hanmi Pharm achieved feat by exporting diabetes treatment drugs from JP Morgan Healthcare in 2016 and obesity treatment technology in 2018.
In addition, AVL Bio, Genome & Company, MedFacto, Apta Bio, NG Chem Life Science, and SM Life Science have announced that they plan to seek partner meetings.
Hye-min Heo, a researcher at Kiwoom Securities, said, “The KOSPI pharmaceutical index has been adjusted due to profit realization after JP Morgan Healthcare and the beginning of the fourth quarter earnings season.” Technology contracts and mergers and acquisitions (M&A) are also announced at this time, so they can be used to cover related shares.”
In addition, Ka-Hye Hong, a researcher at KB Securities, added, “A number of biotech companies will attend and seek partner meetings.”